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7LETTER TO THE EDITOR
e: Failure to Engraft after Autologous Stem Cell
ransplantation: Possible Therapeutic Role
f Cyclosporine
With adequate stem cell dose (CD-34 cells to achieve complete remission with stem cell sup-p
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O2.5106/kg), graft failure in autologus transplant is
ncommon [1-3]. Hematopoietic graft failure can be
eﬁned, as failure of granulocyte counts to reach 0.5
09/L by day 28 [1-2]. Insufﬁcient numbers of hema-
opoietic precursor cells, infections, drugs, defective
one marrow microenvironment, previous heavy che-
otherapy and possible autoimmune mechanisms can
ead to graft failure. In most cases however the cause
emains obscure.
We herein report a 44-year-old woman with stage
II large cell anaplastic (Ki-1) lymphoma who received
alvage high dose chemotherapy and autologus pe-
ipheral blood stem cell transplantation. Her previous
hemotherapy included, 6 cycles of CHOP (cyclo-
hosphamide, doxorubicin, vincristine, prednisone), 2
ycles of hyper- CVAD (cyclophosphamide, vincris-
ine, doxorubicin, dexamethasone), and 3 cycles of
CE (ifosfamide, carboplatin, etoposide) regimens.
ith these, she had excellent partial responses (90%
eduction). However her disease persisted and grew
etween chemotherapy cycles. She did not receive
ituximab (T-cell NHL). She was conditioned with
EAM (BCNU, etoposide, cytarabine and melphalan)
n myeloablative doses. A total of 3.77  106/kg G-
SF mobilized CD-34 cells were infused. Granulo-
yte colony stimulating factor (G-CSF) at 600 ug daily
as initiated from day 7. On day 18, the dose of
-CSF was doubled to 600 g twice a day. She had no
omplications or infection during the course of trans-
lant. Failure to engraft led to a bone marrow biopsy
n day 28 revealing severe bone marrow hypoplasia.
o additional autologus stem cells were available. A
earch for cord blood and HLA matching of family
onors was initiated. Empiric cyclosporine therapy
150 mg PO BID) from day 28 resulted in a surge of
eutrophil counts within a week (Table 1). She failedNC indicates absolute neutrophil count.
4orted high dose chemotherapy.
Most centers treat such failure with growth factors
nd additional infusion of CD-34 cells around day
18-28 [2-3]. T-cell mediated immune mechanisms
ave been implicated for bone marrow failure syn-
romes [4]. Empiric cyclosporine therapy was there-
ore attempted. The case presented thus illustrates a
ossible role of cyclosporine in restoring hematopoi-
sis. However, a larger experience is required to deﬁne
ny potential role of cyclosporine in this setting.
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klahoma City, OKable 1. Engraftment Data
Variable
Day
18 22 28 30 32 34 36 38 40
NC 80 112 112 280 408 720 1281 2230 4960
latelets 34 20 9 21 32 19 15 15 45
